Jaffee EM - Search Results

1

Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response.

Ercolini AM, Ladle BH, Manning EA, Pfannenstiel LW, Armstrong TD, Machiels JP, Bieler JG, Emens LA, Reilly RT, Jaffee EM. Ercolini AM, et al. Among authors: jaffee em. J Exp Med. 2005 May 16;201(10):1591-602. doi: 10.1084/jem.20042167. Epub 2005 May 9. J Exp Med. 2005. PMID: 15883172 Free PMC article.

2

A reassessment of the role of B7-1 expression in tumor rejection.

Wu TC, Huang AY, Jaffee EM, Levitsky HI, Pardoll DM. Wu TC, et al. Among authors: jaffee em. J Exp Med. 1995 Nov 1;182(5):1415-21. doi: 10.1084/jem.182.5.1415. J Exp Med. 1995. PMID: 7595212 Free PMC article.

3

Cancer vaccines.

Greten TF, Jaffee EM. Greten TF, et al. Among authors: jaffee em. J Clin Oncol. 1999 Mar;17(3):1047-60. doi: 10.1200/JCO.1999.17.3.1047. J Clin Oncol. 1999. PMID: 10071300 Review.

4

Immunotherapy of cancer.

Jaffee EM. Jaffee EM. Ann N Y Acad Sci. 1999;886:67-72. doi: 10.1111/j.1749-6632.1999.tb09401.x. Ann N Y Acad Sci. 1999. PMID: 10667204 Review.

5

Potential role of tumor vaccines in GI malignancies.

Laheru DA, Jaffee EM. Laheru DA, et al. Among authors: jaffee em. Oncology (Williston Park). 2000 Feb;14(2):245-56; discussion 259-60, 265. Oncology (Williston Park). 2000. PMID: 10736811 Free article. Review.

6

HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice.

Reilly RT, Gottlieb MB, Ercolini AM, Machiels JP, Kane CE, Okoye FI, Muller WJ, Dixon KH, Jaffee EM. Reilly RT, et al. Among authors: jaffee em. Cancer Res. 2000 Jul 1;60(13):3569-76. Cancer Res. 2000. PMID: 10910070

7

Intracranial paracrine interleukin-2 therapy stimulates prolonged antitumor immunity that extends outside the central nervous system.

Ewend MG, Thompson RC, Anderson R, Sills AK, Staveley-O'Carroll K, Tyler BM, Hanes J, Brat D, Thomas M, Jaffee EM, Pardoll DM, Brem H. Ewend MG, et al. Among authors: jaffee em. J Immunother. 2000 Jul-Aug;23(4):438-48. doi: 10.1097/00002371-200007000-00007. J Immunother. 2000. PMID: 10916753

8

The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors.

Reilly RT, Machiels JP, Emens LA, Ercolini AM, Okoye FI, Lei RY, Weintraub D, Jaffee EM. Reilly RT, et al. Among authors: jaffee em. Cancer Res. 2001 Feb 1;61(3):880-3. Cancer Res. 2001. PMID: 11221874

9

Chemotherapy: friend or foe to cancer vaccines?

Emens LA, Machiels JP, Reilly RT, Jaffee EM. Emens LA, et al. Among authors: jaffee em. Curr Opin Mol Ther. 2001 Feb;3(1):77-84. Curr Opin Mol Ther. 2001. PMID: 11249735 Review.

10

Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice.

Machiels JP, Reilly RT, Emens LA, Ercolini AM, Lei RY, Weintraub D, Okoye FI, Jaffee EM. Machiels JP, et al. Among authors: jaffee em. Cancer Res. 2001 May 1;61(9):3689-97. Cancer Res. 2001. PMID: 11325840

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

327 results

Search Page